Maintenance ZD1839 (IRESSA®) Following Completion of Front Line, Platinum-Based, Double Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer

NCT00090675 · clinicaltrials.gov ↗

PHASE3

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped No patients randomised

Conditions

Non-Small-Cell Lung Carcinoma

Interventions

DRUG: ZD1839

Sponsor

AstraZeneca